引用本文: | 康晓征, 闫万璞, 陈克能, 唐文芳. 厄洛替尼与标准一线化疗作为新辅助治疗ⅢA-N2期EGFR突变阳性非小细胞肺癌患者的疗效比较[J]. 循证医学, 2019, 19(1): 30-33. DOI: 10.12019/j.issn.1671-5144.2019.01.009 |
Citation: | KANG Xiao-zheng, YAN Wan-pu, CHEN Ke-neng, TANG Wen-fang. Erlotinib Versus Standard First-Line Chemotherapy as Neoadjuvant Treatment for Stage ⅢA-N2 EGFR-Mutation Positive Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(1): 30-33. DOI: 10.12019/j.issn.1671-5144.2019.01.009 |